eli lilly and company

Eli Lilly is offering weight loss drug Zepbound

Eli Lilly cuts prices for Zepbound weight-loss drug again

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Investopedia on MSN · 16h

Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

YAHOO!Finance · 23h

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program.1 Lilly also reduced the price of the 2.

21h

Eli Lilly: Load Up Before It Leaves You Behind

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

FierceBiotech1h

Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Yahoo Finance4d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...

M&A News: Eli Lilly (LLY) Expands IBD Pipeline with Organovo’s FXR Program

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...